Bristol-Myers Squibb Joins Oslo Cancer Cluster.New Initiative Aims to be Europe's Leading Center for Diagnostics and Treatment by 2015 BOSTON, Mass. -- Oslo Cancer Cluster cancer cluster Epidemiology A cancer that occurs in a group of people living or working in a geographically defined region who may share one or more environmental factors–eg, DES, and a characteristic lesion–eg, vaginal adenoCA, in common. See Clusters. today announced at BIO2007 that Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Norway is the latest leading pharmaceutical company to join this major private-public initiative in one of Europe's rising biopharma regions. Established around the Radium radium (rā`dēəm) [Lat. radius=ray], radioactive metallic chemical element; symbol Ra; at. no. 88; at. wt. 226.0254; m.p. 700°C;; b.p. 1,140°C;; sp. gr. about 6.0; valence +2. Radium is a lustrous white radioactive metal. Hospital, which has the same Comprehensive Cancer Center status as leading US institutions as Dana Farber, MD Anderson and Sloan Kettering, the Oslo Cancer Cluster aims to become the most innovative center in Europe for cancer diagnostics and treatment by 2015. BIO2007 comes in the middle of a launch visit to the US which includes presentations in Research Triangle Park Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. and Boston. Dr. Ivar Jonsson, Medical Science Manager Oncology, explained Bristol-Myers Squibb Norway's decision: "We welcome this initiative, having had a long history of successful collaboration with Oslo institutions in relation to the development of Taxol, in particular for various indications, specifically with a focus on gynaecological adj. 1. Of or pertaining to gynecology; same as gynecological. Adj. 1. gynaecological - of or relating to or practicing gynecology; "gynecological examination" gynecologic, gynecological cancers. We are currently conducting or supporting several phase II trials, mainly within the field of leukemia, melanoma and breast cancer, and we are aiming at launching several new oncology compounds in the coming years. Further concentrating resources in the Oslo Cancer Cluster will we believe create a powerhouse for oncology research and development." A delighted Jonas Einarsson, Chairman of the Oslo Cancer Cluster, commented: "There is no doubt that the initiative is setting up in the right place and at the right time. Oslo has all the required elements for success: research institutes, hospitals, Phase I units, an epidemiological network, represented by the Norwegian Cancer Registry, and a strong industrial base of around 25 oncology-related companies ranging from spinouts to big pharma. With these resources we aim to develop strong areas of cancer research including immunotherapy, breast cancer genomics and proteomics, cancer stem cell Cancer stem cell hypothesis states that tumors arise from cells termed cancer stem cells that have properties of adult stem cells, particularly the abilities to self-renew and differentiate into multiple cell types, and that these cells persist in tumors as a distinct population biology, and photodynamic therapy photodynamic therapy n. A type of phototherapy in which a nontoxic light-sensitive compound that has been injected into a patient is exposed selectively to light, whereupon it becomes toxic to targeted malignant and other diseased cells. and provide the framework for their translation into new therapeutics for the benefit of cancer patients." For more information and list of members please visit www.oslocancercluster.org |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion